Rocket Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Rocket Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 51.5% e 51.3% all'anno. Si prevede che l'EPS crescerà di 51.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -35.4% in 3 anni.

Informazioni chiave

51.5%

Tasso di crescita degli utili

51.3%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	26.8%
Tasso di crescita dei ricavi	51.3%
Rendimento futuro del capitale proprio	-35.4%
Copertura analitica	Good
Ultimo aggiornamento	30 Dec 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Jul 08

Rocket Pharma: Poised For Growth In The Rare Disease Space

Jun 30

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Jan 30

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

Rocket earns Evercore nod after positive data for rare genetic disease

Dec 17

Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial

Dec 09

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:RCKT - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	477	-23	-86	17	5
12/31/2026	165	-205	-185	-117	10
12/31/2025	56	-238	-236	-168	14
12/31/2024	0	-267	-251	-214	12
9/30/2024	N/A	-258	-202	-192	N/A
6/30/2024	N/A	-253	-210	-197	N/A
3/31/2024	N/A	-249	-210	-194	N/A
12/31/2023	N/A	-246	-211	-195	N/A
9/30/2023	N/A	-253	-236	-222	N/A
6/30/2023	N/A	-249	-219	-208	N/A
3/31/2023	N/A	-237	-206	-196	N/A
12/31/2022	N/A	-222	-186	-178	N/A
9/30/2022	N/A	-199	-160	-153	N/A
6/30/2022	N/A	-192	-147	-137	N/A
3/31/2022	N/A	-172	-145	-136	N/A
12/31/2021	N/A	-169	-129	-121	N/A
9/30/2021	N/A	-186	-122	-103	N/A
6/30/2021	N/A	-165	-108	-93	N/A
3/31/2021	N/A	-155	-92	-77	N/A
12/31/2020	N/A	-140	-95	-75	N/A
9/30/2020	N/A	-99	-98	-81	N/A
6/30/2020	N/A	-89	-98	-75	N/A
3/31/2020	N/A	-82	-99	-71	N/A
12/31/2019	N/A	-77	-88	-65	N/A
9/30/2019	N/A	-85	-81	-66	N/A
6/30/2019	N/A	-82	-75	-67	N/A
3/31/2019	N/A	-79	-60	-58	N/A
12/31/2018	N/A	-75	-55	-54	N/A
9/30/2018	N/A	-54	-40	-39	N/A
6/30/2018	N/A	-44	N/A	-31	N/A
3/31/2018	N/A	-32	N/A	-24	N/A
12/31/2017	N/A	-20	N/A	-16	N/A
9/30/2017	N/A	-16	N/A	-12	N/A
6/30/2017	N/A	-11	N/A	-9	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che RCKT rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che RCKT rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che RCKT rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di RCKT ( 51.3% all'anno) crescerà più rapidamente del mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di RCKT ( 51.3% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che RCKT non sarà più redditizia tra 3 anni.

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/01/05 02:18
Prezzo dell'azione a fine giornata	2025/01/03 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Rocket Pharmaceuticals, Inc. è coperta da 25 analisti. 14 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Jason Zemansky	BofA Global Research
Gregory Harrison	BofA Global Research
Yun Zhong	BTIG

Rocket Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates fall by 11%

Consensus revenue estimates decrease by 57%, EPS upgraded

No longer forecast to breakeven

Forecast to breakeven in 2026

Consensus revenue estimates fall by 95%

Price target decreased to US$53.18

Recent updates

Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $165 million.

Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $165 million.

Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

CEO & Director recently sold US$229k worth of stock

CEO & Director notifies of intention to sell stock

Consensus revenue estimates fall by 11%

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Independent Director notifies of intention to sell stock

Insider recently sold US$309k worth of stock

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Consensus revenue estimates decrease by 57%, EPS upgraded

VP, Senior Controller notifies of intention to sell stock

Rocket Pharmaceuticals' Promising Path In Gene Therapy

No longer forecast to breakeven

New minor risk - Insider selling

CEO & Director recently sold US$605k worth of stock

CEO & Director notifies of intention to sell stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold US$88k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 95%

CEO & Director notifies of intention to sell stock

Insider recently sold US$68k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others,

Now 23% undervalued

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President

Price target decreased to US$53.18

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Rocket Pharma: Poised For Growth In The Rare Disease Space

Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Price target decreased to US$58.50

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022

Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

Price target decreased to US$63.56

Consensus forecasts updated

CEO & Director recently bought US$382k worth of stock